Partners in the international consortium CAR T-REX announce the awarding of a highly competitive EIC Pathfinder Open grant, following the positive evaluation of their project entitled ‘CAR T Cells Rewired to Prevent EXhaustion in the Tumour Microenvironment’.
What the Sarepta decision means for Duchenne patients, the company, and the FDA
Sarepta Therapeutics always wins. That was a given, even before the Food and Drug Administration expanded approval of the company’s Duchenne muscular dystrophy drug on